




SEPTEMBER 2014, Vol. 15, No. 3   SAJHIVMED     77
FORUM
One size doesn’t fit all: Tailoring adult 
antiretroviral treatment
N Geffen,1 MSc; M Robinson,2 BSc Hons; F Venter,3 FCP (SA); M Low,4 MA, MPhil
1 Centre for Social Science Research, University of Cape Town, South Africa 
2 Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa 
3 Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 Policy Department, Treatment Action Campaign, Cape Town, South Africa
Corresponding author: N Geffen (nathangeffen@gmail.com)
Advances in antiretroviral treatment mean that patients in the public health system can be given more options in the management 
of their treatment. Although public health programmes tend to offer one-size-fits-all approaches, patients might benefit from 
a more flexible approach. In particular, we propose that people with HIV should be given more choice with regard to when to 
start treatment, and patients who experience efavirenz side-effects should be encouraged to switch to other medications, which 
will be facilitated by faster registration and lower prices of newer antiretrovirals. 
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In the past decade, the standard of care for HIV 
treatment in the public sector has improved 
considerably. Our increased knowledge of 
antiretroviral (ARV) medicines and the 
additional drugs in our treatment arsenal are an 
oppor tunity to give patients a greater number of options and 
improve the tolerability of treatment.  
When the state’s antiretroviral therapy (ART) roll-out began 
in 2004, the CD4+ initiation threshold for adults was 200 cells/µl 
and the first-line regimen included stavudine, a drug associated 
with severe side-effects. A decade later, the CD4+ threshold 
is 350 cells/µl,[1] and will be increased soon to 500 cells/µl.[2] 
Additionally, stavudine has been replaced with a safer alternative, 
tenofovir. While 10 years ago, adults on their first regimen had 
to take varied-dose combinations twice daily, today most patients 
are being prescribed one pill once daily. This progress has 
resulted in ART that is easier to manage and maintain. 
Public health programmes need to standardise the care 
offered to patients. But a one-size-fits-all approach can be too 
restrictive, resulting in some patients receiving suboptimal 
care. There is scope to offer more options to patients with HIV, 
at least in some facilities, with the prospect of improving their 
quality of life. This increased individualisation of treatment is 
unlikely to overburden the public health system. While there 
are a number of factors that affect individualising treatment, 
here we focus on two that we believe can be adapted in public-
sector ART programmes in South Africa (SA): (i) efavirenz 
tolerability; and (ii) treatment initiation. 
Efavirenz tolerability
In 2014, ART options are relatively plentiful, but several 
important ones are, for the most part, beyond the public sector. 
Besides nucleoside and non-nucleoside reverse transcriptase 
inhibitors and protease inhibitors, integrase inhibitors are 
now also available in the private sector, but access is limited to 
specific research and clinical scenarios in public facilities. 
The current first-line regimen includes efavirenz, which is 
tolerated well by most patients. Given that over 2.5 million 
patients are receiving treatment in the public sector, about 2 
million are likely to be receiving efavirenz. But some patients 
endure debilitating neurocognitive side-effects from this drug; 
recent data suggest a doubling of the suicide rate in people 
treated with efavirenz over other regimens.[3] Patients should 
have the opportunity to modify their regimen by switching 
efavirenz for a protease or integrase inhibitor.
The concern is the price and availability of alternative drugs. 
The standard first-line efavirenz-containing regimen costs the 
state less than R100 per patient per month. Protease inhibitors 
cost more, but have become increasingly affordable. Raltegravir, 
however, is not readily available in the public sector, is on the 
state tender at R533 per patient per month,[4] and is currently 
dosed twice daily. New integrase inhibitors like the daily-dosed 
dolutegravir are not yet available in SA, and the local price is 
as yet unknown. 
The lag times between ARVs being approved by the US Food 
and Drug Administration, European Medicines Agency v. the 
Medicines Control Council (MCC) are extraordinarily long, 
especially considering that there is much greater need in SA and 
other sub-Saharan African countries than in North America or 
Europe. To improve treatment options for patients, clinicians, 
researchers and activists need to put pressure on pharmaceutical 
companies and the MCC to prioritise registration here (and in 
other African countries). Campaigning for lower prices of new 
ARV drugs must continue.
Treatment initiation
The HPTN 052[5] and PARTNER[6] studies show that HIV-
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treatment will not transmit the virus to HIV-negative sexual partners. 
Also, clinical trial evidence shows that it is clinically beneficial to initiate 
treatment at a CD4+ count of 350 v. 250 cells/µl.[7] But the optimal 
CD4+ threshold to initiate patients to maximise clinical benefit remains 
unknown. It is possible that the benefits of starting above 350 cells/µl may 
be undone by interrupted drug supplies or if poor adherence results in the 
emergence of drug resistance. Within the next 3 years, the START[8] and 
TEMPRANO[9] clinical trials are likely to provide a clearer answer on the 
clinical benefits and risks of initiating treatment above 350 cells/µl. 
But without clear evidence that the clinical benefit of earlier 
treatment outweighs harm due to side-effects, patients should be given 
the opportunity to make an informed choice. Their pathophysiology, 
preferences and circumstances should be taken into account to 
determine when it is appropriate to initiate treatment. The question 
of when to start treatment has become contentious, and many experts 
differ on this issue. This is understandable, given the current lack of 
evidence about the clinical and the public health benefits of suppressing 
viral load in sexually active people with HIV. 
There is increasing pressure on people with HIV to start treatment 
earlier, e.g. at 500 cells/µl. The World Health Organization raised the 
CD4+ threshold for initiating ART to 500 cells/µl in its 2013 treatment 
guidelines.[10] The SA Minister of Health has announced that this 
threshold will also be used in SA from January 2015.[2]  In response to 
the Minister’s announcement, the Southern African HIV Clinicians 
Society correctly wrote: ‘We … support an individualised approach 
in patients with a CD4+ count 350 - 500 [cells/µl]: after a discussion 
about the potential benefits, uncertainties, side-effects and need for 
impecable [sic] adherence patients should only be prescribed ART in 
this CD4+ range if they are motivated for lifelong ART with the required 
adherence. If they do not feel ready yet, ART should be deferred until 
their CD4+ count is below 350 [cells/µl] with a plan in place for ongoing 
follow-up and CD4+ monitoring.’[11]
Furthermore, the threshold of 500 cells/µl is arbitrary and not based 
on clinical trial findings. We therefore propose the following approach: 
ART should be offered to all people with HIV. As part of discussions 
between patients and providers, patients need to be given an informed 
choice.
Patients with CD4+ counts >350 cells/µl should be informed that the 
clinical benefits and risks of starting ART at high CD4+ counts are, as 
yet, unknown, and that taking treatment daily is likely to be a life-long 
commitment. Patients should also be informed that within a few years, 
more will be known about this. 
Patients who are sexually active and want to minimise their risk of 
transmission to sexual partners should be informed that treatment can 
reduce the risk of transmitting HIV considerably, at least once viral load 
becomes undetectable.
Based on this information, patients who wish to start at a high CD4+ 
count should be allowed to do so. There are caveats: Early ART is not 
a reasonable option in facilities still using stavudine or zidovudine as 
first-line treatment, nor in facilities prone to stock-outs. In resource-
stretched facilities with high patient loads, patients with CD4+ counts 
<350 cells/µl must be prioritised. Ultimately, an approach that gives 
patients the opportunity to make informed choices respects the 
principle of patient autonomy. This could lead to increased adherence, 
and better outcomes for individual patient’s and the public’s health.
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